androgenetic alopecia
Conditions
Interventions
Intervention group:Receive local injection of autologous platelet dry powder reconstituted solution
Control group:Receive routine CGF local injection
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 - 60 years old. Gender: Open to all. 2.The clinical diagnosis is androgenetic alopecia (for men with Hamilton-Norwood classification IIIv-V or for women with Ludwig classification I-2), and it is in a stable stage. 3.No use of oral medications such as finasteride or dutasteride within the past 6 months; no use of topical hair growth medications like minoxidil or other hair loss treatments within the past 3 months, nor any other hair loss treatments such as PRP or laser therapy. 4.Platelet count and coagulation function are normal, and there is no blood system disease. 5.Weight >= 50kg, meeting the requirements for platelet collection by the blood cell separator machine; 6.No history of blood transfusion or use of blood products in the past 3 months. 7.Voluntarily participate and sign a written informed consent form, and be able to understand and follow the research procedures;
Exclusion criteria
Exclusion criteria: 1.Scarring alopecia, acute progression of alopecia areata, or other active scalp disorders; 2.Having severe heart, liver, kidney, autoimmune diseases, malignant tumors or active infections; 3.Those with coagulation dysfunction or who are currently taking anticoagulant/antiplatelet medications (those who no longer meet the coagulation requirements after discontinuation of the medication); 4.Pregnant women, lactating women or those planning to become pregnant within the next 6 months; 5.It is known that one is allergic to the components related to the research intervention (such as heparin sodium, activator, and normal saline); 6.Those with contraindications for platelet collection (such as severe vascular malformations, severe anemia, positive indicators of infectious diseases, etc.); 7.Those who have previously received autologous platelet products treatment and experienced adverse reactions; 8.Other circumstances that the researchers determined were not suitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in hair density in the target treatment area;Change in hair thickness in the target treatment area; | — |
Secondary
| Measure | Time frame |
|---|---|
| Subjective efficacy and patient perception evaluation;Correlation between growth factor concentration and efficacy;Assessment of formulation stability; | — |
Countries
China
Contacts
Public ContactCai Xiaohong
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed